Physician profile
Jivesh Sharma
NPI 1588653406
$13,965.71
in general payments reported to CMS, 2019-2025
95 companies · $2,170 in 2025
The $2,170 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,010 · 2020: $1,182 · 2021: $2,767 · 2022: $2,338 · 2023: $916 · 2024: $2,584 · 2025: $2,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,472 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,471.82 |
| Education | $197.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $977.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $911.78 | 2019-2025 | |
| Astellas Pharma US INC | $841.20 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Astrazeneca Pharmaceuticals LP | $675.17 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Janssen Biotech, INC. | $645.47 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $635.71 | 2019-2024 | Keytruda, Lynparza, Reblozyl |
| Incyte Corporation | $550.32 | 2019-2025 | Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $501.76 | 2019-2025 | Opdivo, Opdualag |
| Eisai INC. | $386.20 | 2020-2025 | |
| Celgene Corporation | $383.03 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $359.24 | 2019-2025 | Trodelvy |
| Abbvie INC. | $357.63 | 2020-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $335.42 | 2020-2025 | |
| Genzyme Corporation | $304.72 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $294.20 | 2019-2025 | Provenge |
Show all 95 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jivesh Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.